Calmodulin Levels in Blood Cells As a Potential Biomarker of Alzheimer's Disease

Overview

Journal Alzheimers Res Ther

Date 2014 Feb 7

PMID 24499616

Citations 9

Authors

Noemi Esteras

Carolina Alquezar

Ana de la Encarnacion

Alberto Villarejo

Felix Bermejo-Pareja

Angeles Martin-Requero

Affiliations

Soon will be listed here.

Abstract

Introduction: The clinical features of Alzheimer's disease (AD) overlap with a number of other dementias and conclusive diagnosis is only achieved at autopsy. Accurate in-life diagnosis requires finding biomarkers suitable for early diagnosis, as well as for discrimination from other types of dementia. Mounting evidence suggests that AD-dependent processes may also affect peripheral cells. We previously reported that calmodulin (CaM) signaling is impaired in AD lymphoblasts. Here, we address the issue as to whether the assessment of CaM levels in peripheral cells could serve as a diagnostic biomarker.

Methods: A total of 165 subjects were enrolled in the study, including 56 AD patients, 15 patients with mild cognitive impairment, 7 with frontotemporal dementia associated with progranulin mutations, 4 with dementia with Lewy bodies, 20 patients with Parkinson's disease, 10 with amyotrophic lateral sclerosis, 5 with progressive supranuclear palsy, and 48 cognitively normal individuals. CaM levels were then analyzed in lymphoblasts, peripheral blood mononuclear cells and plasma. Receiver operating characteristic (ROC) curve analyses were employed to evaluate the diagnostic performance of CaM content in identifying AD patients.

Results: Compared with control individuals, CaM levels were significantly increased in AD cells, but not in the other neurodegenerative disorders. CaM levels differentiated AD from control with a sensitivity of 0.89 and a specificity of 0.82 and were not dependent on disease severity or age. MCI patients also showed higher levels of the protein.

Conclusions: CaM levels could be considered a peripheral biomarker for AD in its early stage and help to discriminate from other types of dementia.

Citing Articles

In-Silico Multi-Omics Analysis of the Functional Significance of Calmodulin 1 in Multiple Cancers.

Yao M, Fu L, Liu X, Zheng D Front Genet. 2022; 12:793508.

PMID: 35096010 PMC: 8790318. DOI: 10.3389/fgene.2021.793508.

Gene network analysis to determine the effect of hypoxia-associated genes on brain damages and tumorigenesis using an avian model.

Kharrati-Koopaee H, Ebrahimie E, Dadpasand M, Niazi A, Tian R, Esmailizadeh A J Genet Eng Biotechnol. 2021; 19(1):100.

PMID: 34236536 PMC: 8266987. DOI: 10.1186/s43141-021-00184-5.

Mitochondrial Calcium Deregulation in the Mechanism of Beta-Amyloid and Tau Pathology.

Esteras N, Abramov A Cells. 2020; 9(9).

PMID: 32967303 PMC: 7564294. DOI: 10.3390/cells9092135.

Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment.

Martinez-Gonzalez L, Rodriguez-Cueto C, Cabezudo D, Bartolome F, Andres-Benito P, Ferrer I Sci Rep. 2020; 10(1):4449.

PMID: 32157143 PMC: 7064575. DOI: 10.1038/s41598-020-61265-y.

Luminescent and paramagnetic properties of nanoparticles shed light on their interactions with proteins.

Dal Cortivo G, Wagner G, Cortelletti P, Padmanabha Das K, Zangger K, Speghini A Sci Rep. 2018; 8(1):3420.

PMID: 29467422 PMC: 5821874. DOI: 10.1038/s41598-018-21571-y.

References

Esteras N, Alquezar C, Bermejo-Pareja F, Bialopiotrowicz E, Wojda U, Martin-Requero A . Downregulation of extracellular signal-regulated kinase 1/2 activity by calmodulin KII modulates p21Cip1 levels and survival of immortalized lymphocytes from Alzheimer's disease patients. Neurobiol Aging. 2012; 34(4):1090-100. DOI: 10.1016/j.neurobiolaging.2012.10.014. View

Tan M, Wang S, Song J, Jia J . Combination of p53(ser15) and p21/p21(thr145) in peripheral blood lymphocytes as potential Alzheimer's disease biomarkers. Neurosci Lett. 2012; 516(2):226-31. DOI: 10.1016/j.neulet.2012.03.093. View

McKeith I, Dickson D, Lowe J, Emre M, OBrien J, Feldman H . Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005; 65(12):1863-72. DOI: 10.1212/01.wnl.0000187889.17253.b1. View

de Munain A, Alzualde A, Gorostidi A, Otaegui D, Ruiz-Martinez J, Indakoetxea B . Mutations in progranulin gene: clinical, pathological, and ribonucleic acid expression findings. Biol Psychiatry. 2007; 63(10):946-52. DOI: 10.1016/j.biopsych.2007.08.015. View

Alquezar C, Esteras N, Bartolome F, Merino J, Alzualde A, de Munain A . Alteration in cell cycle-related proteins in lymphoblasts from carriers of the c.709-1G>A PGRN mutation associated with FTLD-TDP dementia. Neurobiol Aging. 2011; 33(2):429.e7-20. DOI: 10.1016/j.neurobiolaging.2010.11.020. View

Mosch B, Morawski M, Mittag A, Lenz D, Tarnok A, Arendt T . Aneuploidy and DNA replication in the normal human brain and Alzheimer's disease. J Neurosci. 2007; 27(26):6859-67. PMC: 6672221. DOI: 10.1523/JNEUROSCI.0379-07.2007. View

Davidkova G, Zhang S, Nichols R, Weiss B . Reduced level of calmodulin in PC12 cells induced by stable expression of calmodulin antisense RNA inhibits cell proliferation and induces neurite outgrowth. Neuroscience. 1996; 75(4):1003-19. DOI: 10.1016/0306-4522(96)00230-8. View

Blennow K, Hampel H . CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003; 2(10):605-13. DOI: 10.1016/s1474-4422(03)00530-1. View

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

10.

McShea A, Lee H, Petersen R, Casadesus G, Vincent I, Linford N . Neuronal cell cycle re-entry mediates Alzheimer disease-type changes. Biochim Biophys Acta. 2006; 1772(4):467-72. DOI: 10.1016/j.bbadis.2006.09.010. View

11.

Gauthier S, Reisberg B, Zaudig M, Petersen R, Ritchie K, Broich K . Mild cognitive impairment. Lancet. 2006; 367(9518):1262-70. DOI: 10.1016/S0140-6736(06)68542-5. View

12.

Rickle A, Bogdanovic N, Volkman I, Winblad B, Ravid R, Cowburn R . Akt activity in Alzheimer's disease and other neurodegenerative disorders. Neuroreport. 2004; 15(6):955-9. DOI: 10.1097/00001756-200404290-00005. View

13.

de Las Cuevas N, Urcelay E, Hermida O, Saiz-Diaz R, Bermejo F, Ayuso M . Ca2+/calmodulin-dependent modulation of cell cycle elements pRb and p27kip1 involved in the enhanced proliferation of lymphoblasts from patients with Alzheimer dementia. Neurobiol Dis. 2003; 13(3):254-63. DOI: 10.1016/s0969-9961(03)00040-8. View

14.

Pellicano M, Bulati M, Buffa S, Barbagallo M, Di Prima A, Misiano G . Systemic immune responses in Alzheimer's disease: in vitro mononuclear cell activation and cytokine production. J Alzheimers Dis. 2010; 21(1):181-92. DOI: 10.3233/JAD-2010-091714. View

15.

Litvan I, Bhatia K, Burn D, Goetz C, Lang A, McKeith I . Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord. 2003; 18(5):467-86. DOI: 10.1002/mds.10459. View

16.

Esteras N, Munoz U, Alquezar C, Bartolome F, Bermejo-Pareja F, Martin-Requero A . Altered calmodulin degradation and signaling in non-neuronal cells from Alzheimer's disease patients. Curr Alzheimer Res. 2011; 9(3):267-77. DOI: 10.2174/156720512800107564. View

17.

Nagy Z, Combrinck M, Budge M, McShane R . Cell cycle kinesis in lymphocytes in the diagnosis of Alzheimer's disease. Neurosci Lett. 2002; 317(2):81-4. DOI: 10.1016/s0304-3940(01)02442-9. View

18.

Migliore L, Fontana I, Trippi F, Colognato R, Coppede F, Tognoni G . Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol Aging. 2005; 26(5):567-73. DOI: 10.1016/j.neurobiolaging.2004.07.016. View

19.

Gelb D, Oliver E, Gilman S . Diagnostic criteria for Parkinson disease. Arch Neurol. 1999; 56(1):33-9. DOI: 10.1001/archneur.56.1.33. View

20.

. Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging. 1998; 19(2):109-16. View